DeuteRx LLC
Deuterium-Enabled Chiral Switching (DECS) technology to isolate and stabilize single stereoisomers from racemic drug mixtures
- Sector
- Biotech
- Headquarters
- ANDOVER, MA
- Founded
- 2012
- Latest Form D
- $2.2M, Sep 2015
- Total capital
- $2.8M
- Federal grants
- $589K
- 2 awards · 2016
- Rank in peer group#102 of 392
- Private capital raised
- $2.2M
- 1 Form D · last Sep 2015
- 133 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 20
- 20 pending · first 2014
- Rank in peer group#7 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Stabilized Prasugrel enantiomers for pediatric sickle cell disease$295K
- Federal grantHealth and Human S · Phase I · Stabilized Prasugrel enantiomers for pediatric sickle cell disease$295K
- Private capital raisedForm D · SEC · 1st filing$2.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#102 · top 26%
- Granted patents#7 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Sheila DeWittResearcherExecutive Officer, DirectorLinked by 5 patents · $589K in grants as PI
- Anthony W. CzarnikDirectorNamed in SEC Form D filings
What it has protected
USPTO · 20 granted of 40- PendingDeuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides And Methods Of Treating Medical Disorders Using SameUSPTOApplication 18957374
- Pending3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameUSPTOApplication 18941986
- GrantedSolid Forms Of Enantiopure Deuterium-enriched Bupropion And Methods Of Use ThereofUSPTOUS 12,180,137
Show all 40 patent records
- Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides And Methods Of Treating Medical Disorders Using SameOct 16, 2025 · Application 18957374Pending
- 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameOct 2, 2025 · Application 18941986Pending
- Solid Forms Of Enantiopure Deuterium-enriched Bupropion And Methods Of Use ThereofDec 31, 2024 · US 12,180,137Granted
- Methods Of Treating Neurological And Other Disorders Using Enantiopure Deuterium-enriched BupropionDec 19, 2024 · Application 18419104Pending
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameNov 21, 2023 · US 11,820,720Granted
- 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameSep 7, 2023 · Application 17959750Pending
- Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides And Methods Of Treating Medical Disorders Using SameAug 3, 2023 · Application 17959751Pending
- Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides And Methods Of Treating Medical Disorders Using SameDec 27, 2022 · US 11,535,603Granted
- 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameNov 8, 2022 · US 11,491,156Granted
- Methods Of Treating Neurological And Other Disorders Using Enantiopure Deuterium-enriched BupropionJul 7, 2022 · Application 17691922Pending
- Methods Of Treating Neurological And Other Disorders Using Enantiopure Deuterium-enriched BupropionDec 16, 2021 · Application 17158405Pending
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameJun 22, 2021 · US 11,040,925Granted
- 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameFeb 11, 2020 · US 10,555,946Granted
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameFeb 12, 2019 · US 10,202,316Granted
- Deuterium-enriched Isoindolinonyl-piperidinonyl Conjugates And OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL Conjugates And Methods Of Treating Medical Disorders Using SameJan 29, 2019 · US 10,189,858Granted
- Methods Of Treating Neurological, Metabolic, And Other Disorders Using Enantiopure Deuterium-enriched PioglitazoneJan 29, 2019 · US 10,188,639Granted
- 2',6'-DIOXO-3'-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE CompoundsNov 15, 2018 · Application 16044816Pending
- 5-DEUTERO-THIAZOLIDINE-2,4-DIONE Compounds And Methods Of Treating Medical Disorders Using SameMay 10, 2018 · Application 15705544Pending
- 5-DEUTERO-THIAZOLIDINYLDIONE Compounds And Methods Of Treating Medical Disorders Using SameMay 3, 2018 · Application 15705545Pending
- 2',6'-DIOXO-3'-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE CompoundsMay 3, 2018 · Application 15722187Pending
- Combination Therapy Using Enantiopure, Oxy-substituted, Deuterium-enriched 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES For Treatment Of Medical DisordersMay 3, 2018 · Application 15705541Pending
- Deuterium-enriched PioglitazoneMar 27, 2018 · US 9,925,175Granted
- 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameMar 13, 2018 · US 9,913,845Granted
- 5-DEUTERO-2,4-THIAZOLIDINEDIONE Derivatives And Compositions Comprising And Methods Of Using The SameDec 5, 2017 · US 9,833,445Granted
- Deuterium-enriched Isoindolinonyl-piperidinonyl Conjugates And OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL Conjugates And Methods Of Treating Medical Disorders Using SameNov 7, 2017 · US 9,809,603Granted
- Methods Of Treating Neurological And Other Disorders Using Enantiopure Deuterium-enriched BupropionAug 15, 2017 · US 9,732,031Granted
- 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameJan 10, 2017 · US 9,540,340Granted
- 5-DEUTERO-2,4-THIAZOLIDINEDIONE Derivatives And Compositions Comprising And Methods Of Using The SameAug 16, 2016 · US 9,416,117Granted
- 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE Derivatives And Compositions Comprising And Methods Of Using The SameMar 22, 2016 · US 9,290,475Granted
- 2',6'-DIOXO-3'-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE CompoundsJan 7, 2016 · Application 14744493Pending
- 5-DEUTERO-2,4-THIAZOLIDINEDIONE Derivatives And Compositions Comprising And Methods Of Using The SameMar 3, 2015 · US 8,969,581Granted
- Deuterium-enriched PrasugrelNov 6, 2014 · Application 14175059Pending
- Deuterium-enriched PioglitazoneAug 28, 2014 · Application 14272761Pending
- 5-DEUTERO-2,4-THIAZOLIDINEDIONE And 5-DEUTERO-2,4-OXAZOLIDINEDIONE Derivatives And Compositions Comprising And Methods Of Using The SameAug 7, 2014 · Application 14169380Pending
- Deuterium-enriched BupropionMay 27, 2014 · US 8,735,454Granted
- Deuterium-enriched DonepezilMar 11, 2014 · US 8,669,275Granted
- 2',6'-DIOXO-3'-DEUTERO-PIPERDIN-3-YL-ISOINDOLINE CompoundsApplication PCTUS2012030870Pending
- Solid Forms Of Enantiopure Deuterium-enriched Bupropion And Methods Of Use ThereofApplication 19188813Pending
- Solid Forms Of Enantiopure Deuterium-enriched Bupropion And Methods Of Use ThereofApplication 18882600Pending
- Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides And Methods Of Treating Medical Disorders Using SameApplication 16244218Pending
Related companies, and why
- Praeventix, LLCSimilar federal contract value in Biotech · null in contracts
- ABILITA BIO, INC.Similar federal contract value in Biotech · null in contracts
- ACELOT, INC.Similar federal contract value in Biotech · null in contracts
- FGH BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
- RegulonixSimilar federal contract value in Biotech · null in contracts
- 4E THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .